Prospective study of epigenetic alterations responsible for isolated hemihyperplasia/hemihypoplasia and their association with leg length discrepancy.
Beckwith–Wiedemann syndrome
Hemihyperplasia
Hemihypoplasia
Lateralized overgrowth
Leg length discrepancy
Silver–Russell syndrome
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
09 10 2021
09 10 2021
Historique:
received:
11
05
2021
accepted:
19
09
2021
entrez:
10
10
2021
pubmed:
11
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Hemihyperplasia and hemihypoplasia result in leg length discrepancy (LLD) by causing skeletal asymmetry. Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS) are opposite growth-affecting disorders caused by opposite epigenetic alterations at the same chromosomal locus, 11p15, to induce hemihyperplasia and hemihypoplasia, respectively. Because of their somatic mosaicism, BWS and SRS show a wide spectrum of clinical phenotypes. We evaluated the underlying epigenetic alterations and potential epigenotype-phenotype correlations, focusing on LLD, in a group of individuals with isolated hemihyperplasia/hemihypoplasia. We prospectively collected paired blood-tissue samples from 30 patients with isolated hemihyperplasia/hemihypoplasia who underwent surgery for LLD. Methylation-specific multiplex-ligation-dependent probe amplification assay (MS-MLPA) and bisulfite pyrosequencing for differentially methylated regions 1 and 2 (DMR1 and DMR2) on chromosome 11p15 were performed using the patient samples. Samples from patients showing no abnormalities in MS-MLPA or bisulfite pyrosequencing were analyzed by single nucleotide polymorphism (SNP) microarray and CDKN1C Sanger sequencing. We introduced a metric named as the methylation difference, defined as the difference in DNA methylation levels between DMR1 and DMR2. The correlation between the methylation difference and the predicted LLD at skeletal maturity, calculated using a multiplier method, was evaluated. Predicted LLD was standardized for stature. Ten patients (33%) showed epigenetic alterations in MS-MLPA and bisulfite pyrosequencing. Of these, six and four patients had epigenetic alterations related to BWS and SRS, respectively. The clinical diagnosis of hemihyperplasia/hemihypoplasia was not compatible with the epigenetic alterations in four of these ten patients. No patients showed abnormalities in SNP array or their CDKN1C sequences. The standardized predicted LLD was moderately correlated with the methylation difference using fat tissue (r = 0.53; p = 0.002) and skin tissue (r = 0.50; p = 0.005) in all patients. Isolated hemihyperplasia and hemihypoplasia can occur as a spectrum of BWS and SRS. Although the accurate differentiation between isolated hemihyperplasia and isolated hemihypoplasia is important in tumor surveillance planning, it is often difficult to clinically differentiate these two diseases without epigenetic tests. Epigenetic tests may play a role in the prediction of LLD, which would aid in treatment planning.
Sections du résumé
BACKGROUND
Hemihyperplasia and hemihypoplasia result in leg length discrepancy (LLD) by causing skeletal asymmetry. Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS) are opposite growth-affecting disorders caused by opposite epigenetic alterations at the same chromosomal locus, 11p15, to induce hemihyperplasia and hemihypoplasia, respectively. Because of their somatic mosaicism, BWS and SRS show a wide spectrum of clinical phenotypes. We evaluated the underlying epigenetic alterations and potential epigenotype-phenotype correlations, focusing on LLD, in a group of individuals with isolated hemihyperplasia/hemihypoplasia.
RESULTS
We prospectively collected paired blood-tissue samples from 30 patients with isolated hemihyperplasia/hemihypoplasia who underwent surgery for LLD. Methylation-specific multiplex-ligation-dependent probe amplification assay (MS-MLPA) and bisulfite pyrosequencing for differentially methylated regions 1 and 2 (DMR1 and DMR2) on chromosome 11p15 were performed using the patient samples. Samples from patients showing no abnormalities in MS-MLPA or bisulfite pyrosequencing were analyzed by single nucleotide polymorphism (SNP) microarray and CDKN1C Sanger sequencing. We introduced a metric named as the methylation difference, defined as the difference in DNA methylation levels between DMR1 and DMR2. The correlation between the methylation difference and the predicted LLD at skeletal maturity, calculated using a multiplier method, was evaluated. Predicted LLD was standardized for stature. Ten patients (33%) showed epigenetic alterations in MS-MLPA and bisulfite pyrosequencing. Of these, six and four patients had epigenetic alterations related to BWS and SRS, respectively. The clinical diagnosis of hemihyperplasia/hemihypoplasia was not compatible with the epigenetic alterations in four of these ten patients. No patients showed abnormalities in SNP array or their CDKN1C sequences. The standardized predicted LLD was moderately correlated with the methylation difference using fat tissue (r = 0.53; p = 0.002) and skin tissue (r = 0.50; p = 0.005) in all patients.
CONCLUSIONS
Isolated hemihyperplasia and hemihypoplasia can occur as a spectrum of BWS and SRS. Although the accurate differentiation between isolated hemihyperplasia and isolated hemihypoplasia is important in tumor surveillance planning, it is often difficult to clinically differentiate these two diseases without epigenetic tests. Epigenetic tests may play a role in the prediction of LLD, which would aid in treatment planning.
Identifiants
pubmed: 34627330
doi: 10.1186/s13023-021-02042-6
pii: 10.1186/s13023-021-02042-6
pmc: PMC8501601
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
418Informations de copyright
© 2021. The Author(s).
Références
J Pediatr. 2021 Jul;234:123-127
pubmed: 33465347
Nat Genet. 2014 Nov;46(11):1173-86
pubmed: 25282103
J Med Genet. 2003 Mar;40(3):223-6
pubmed: 12624145
Nat Rev Endocrinol. 2017 Feb;13(2):105-124
pubmed: 27585961
Am J Med Genet A. 2006 Jul 15;140(14):1497-503
pubmed: 16770802
Am J Hum Genet. 2005 Nov;77(5):887-91
pubmed: 16252245
Am J Med Genet A. 2015 Feb;167A(2):287-95
pubmed: 25557259
Am J Med Genet A. 2013 Jan;161A(1):192-7
pubmed: 23197429
Hum Mutat. 2015 Sep;36(9):894-902
pubmed: 26077438
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
J Pediatr Orthop. 2001 Jul-Aug;21(4):549-55
pubmed: 11433174
Am J Med Genet A. 2017 Jul;173(7):1735-1738
pubmed: 28475229
J Hum Genet. 2015 Feb;60(2):91-5
pubmed: 25427884
Chiropr Osteopat. 2005 Jul 20;13:11
pubmed: 16026625
J Pediatr. 2008 Jul;153(1):95-100
pubmed: 18571544
Horm Res Paediatr. 2020;93(1):7-15
pubmed: 31914447
J Bone Joint Surg Am. 1997 Nov;79(11):1731-8
pubmed: 9384434
J Child Orthop. 2016 Aug;10(4):313-9
pubmed: 27357078
Am J Med Genet C Semin Med Genet. 2019 Dec;181(4):693-708
pubmed: 31469230
Nat Rev Endocrinol. 2018 Apr;14(4):229-249
pubmed: 29377879
J Med Genet. 2013 Dec;50(12):823-30
pubmed: 24065356
J Bone Joint Surg Am. 2000 Oct;82(10):1432-46
pubmed: 11057472
J Pediatr. 1982 Jan;100(1):160-5
pubmed: 7057306
Arch Med Sci. 2010 Jun 30;6(3):393-8
pubmed: 22371777
Am J Med Genet A. 2005 Apr 15;134A(2):129-31
pubmed: 15651076
Am J Med Genet A. 2010 Jun;152A(6):1390-7
pubmed: 20503313
Eur J Hum Genet. 2016 Feb;24(2):183-90
pubmed: 25898929
Am J Med Genet C Semin Med Genet. 2010 Aug 15;154C(3):343-54
pubmed: 20803657
Eur J Hum Genet. 2001 Jun;9(6):409-18
pubmed: 11436121
Eur J Hum Genet. 2008 Mar;16(3):328-34
pubmed: 18159214
J Bone Joint Surg Am. 2018 Jul 18;100(14):1217-1222
pubmed: 30020127
N Engl J Med. 2015 Jul 23;373(4):349-56
pubmed: 26154720
Clin Orthop Relat Res. 1982 Jun;(166):199-203
pubmed: 7083673
Am J Hum Genet. 2006 Apr;78(4):604-14
pubmed: 16532391